Horizon Enters into OEM Agreements with Market Leading Next Generation Sequencing Company

12 May 2016 | Press release

  • Two OEM agreements signed to date, with potential for additional agreements to follow

Cambridge, UK 12 May 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announces it has entered into two Original Equipment Manufacture (OEM) agreements with a global market leading Next Generation Sequencing (NGS) platform company, with the potential for additional agreements to follow.

Horizon is a leading provider of highly characterised genetic materials that are used as reference standards for the development and quality control of molecular assays. These reference standards help laboratories to establish and validate their workflows.

Under the terms of the agreements, Horizon will supply two previously developed HDx™ Molecular Reference Standards that cover many of the genes most commonly linked with cancer progression and response to treatment. The Horizon materials will be incorporated into assay kits from the NGS manufacturer for a range of applications including cancer research and diagnostics.

Paul Morrill, President, Products at Horizon Discovery Group commented: "The inclusion of Horizon's Reference Standards as a standard kit component by a leading NGS platform provider demonstrates a shift toward independent and highly characterised reference materials to support the deployment of NGS assays in cancer. We are pleased that Horizon was recognised as having the expertise and scale to be a partner in this program."

Financial details of the agreements were not disclosed.